July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Interferon Alpha-2a: an effective therapeutic option in patients with refractory uveitic cystoid macular edema
Author Affiliations & Notes
  • Luca Cimino
    Ocular Immunology Unit, Azienda USL IRCCS, Reggio Emilia, Reggio Emilia, Italy
  • Luca De Simone
    Ocular Immunology Unit, Azienda USL IRCCS, Reggio Emilia, Reggio Emilia, Italy
    Ophthalmology, Campus Biomedico, Rome, Italy, Rome, Italy
  • Raffaella Aldigeri
    Medicine and Surgery Department, University of Parma, Parma, Italy
  • Valentina Mastrofilippo
    Ocular Immunology Unit, Azienda USL IRCCS, Reggio Emilia, Reggio Emilia, Italy
  • Sylvia Marchi
    Ocular Immunology Unit, Azienda USL IRCCS, Reggio Emilia, Reggio Emilia, Italy
    Ophthalmology, Azienda USL IRCCS, Reggio Emilia, Reggio Emilia, Italy
  • Anna Sangiovanni
    Ocular Immunology Unit, Azienda USL IRCCS, Reggio Emilia, Reggio Emilia, Italy
  • Luigi Fontana
    Ophthalmology, Azienda USL IRCCS, Reggio Emilia, Reggio Emilia, Italy
  • Carlo Salvarani
    Rhumatology, Azienda USL IRCCS, Reggio Emilia, Reggio Emilia, Italy
    Rhumatology, University of Modena and Reggio Emilia, Modena, Italy
  • Footnotes
    Commercial Relationships   Luca Cimino, None; Luca De Simone, None; Raffaella Aldigeri, None; Valentina Mastrofilippo, None; Sylvia Marchi, None; Anna Sangiovanni, None; Luigi Fontana, None; Carlo Salvarani, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 411. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Luca Cimino, Luca De Simone, Raffaella Aldigeri, Valentina Mastrofilippo, Sylvia Marchi, Anna Sangiovanni, Luigi Fontana, Carlo Salvarani; Interferon Alpha-2a: an effective therapeutic option in patients with refractory uveitic cystoid macular edema
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):411.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose :
Cystoid macular edema (CME) represents one of the most serious and challenging complications in uveitis and tends to increase in frequency with the duration of inflammation. The treatment of CME is unsatisfactory, although in some patients, it responds well to conventional therapy. Interferon-alfa 2 a, thanks to its role in promoting tissue homeostasis, could be considered a potent therapeutic agent in retinal vasculitis with macular edema, characterized by leakage of the vascular endothelium. The aim of this study is to test the efficacy of interferon alpha 2a in the treatment of refractory uveitic cystoid macular edema (CME).

Methods :
A retrospective chart review was conducted of patients attending the uveitis clinic at Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, with a diagnosis of refractory uveitic CME who started IFN-alfa-2a therapy from November 2013 to July 2017. Patients with at least 3 months of IFN therapy were included. IFN alfa-2a was administered at an initial dosage of 3 million IU per day, then tapered to a maintenance dosage of 3 million IU every other day. The efficacy of IFN therapy was tested by comparing the visual acuity and central macular thickness (CMT) at the beginning and at the end of follow-up.

Results : Twenty-eight patients (13 males and 15 females, mean age of 46 ± 17 yrs) were included in the analysis. Patients presented a median follow-up of 11 months (IQR:6-21). The median duration of therapy was 12 months (IQR:7-24). After a median follow-up of 11 months, both visual acuity (△RE=0.092±0.25, p=.08 & △LE=0.12±0.26, p=.03) and CMT improved significantly in both eyes (△RE=93±210 mm, p=.046 & △LE=155±198 mm, p=.001).

Conclusions : IFN alfa-2a could be included in the therapeutic algorithm of longstanding, recurrent post-uveitic CME with or without retinal vasculitis as it leads to significant reduction of CME and improvement of vision.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×